RxDoctor Payments Data

Douglas Stoller, MD

Advanced Heart Failure and Transplant Cardiology · Omaha, NENPI 1619107851

Payments from drug & device makers

$645,230in general payments, 2019–2025

Across 157 payments — averaging $4109.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$330K
  • Amgen$293K
  • Sanofi US Services Inc.$17K
  • Abbott$3K
  • Medtronic$561
  • Vertex$492
  • plus $727 from 8 others

What the payments were for

  • Consulting fees$10,96721%
  • Speaking & faculty fees$36,34668%
  • Travel & lodging$1,7253%
  • Food & beverage$4,1818%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.36$330,044
Amgen12$293,161
Sanofi US Services Inc.2$17,400
Abbott62$2,844
Medtronic(2 entities)7$561
Vertex1$492
Novartis22$354
Cvrx, Inc.1$137
Pfizer9$134
Bayer1$22
AstraZeneca1$22
Impulse Dynamics (USA) Inc.1$21
Analog Devices Inc.1$21
Abiomed1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$73,585
Medicare patients
227
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis24$509,508
VyndaqelTafamidis Meglumine13$272,610
CamzyosMavacamten21$168,208
EntrestoSacubitril/Valsartan144$154,711
EliquisApixaban46$55,072
JardianceEmpagliflozin46$54,074
FarxigaDapagliflozin Propanediol54$47,828
XareltoRivaroxaban19$24,504
Sirolimus20$20,494
Repatha SureclickEvolocumab16$11,121
Everolimus17$8,240
NeoralCyclosporine, Modified13$7,908
Tacrolimus64$7,570
Potassium Chloride96$3,175
Metoprolol Succinate145$2,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$134$837,19083 claims
E.r. Squibb & Sons, L.L.C.Camzyos$330,044$168,20821 claims
NovartisEntresto$354$154,711144 claims
AstraZenecaFarxiga$22$47,82854 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Nebraskaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Omaha

Where these figures come from

Is this you, or does something look wrong? →